Authors: Stephanie T. de Leon, MD and Ma. Jasmin J. Jamora, MD, FPDS


Introduction: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. Despite this, much is unknown about the initial triggers of the disease. Gliptins, a newly introduced oral medication for type 2 diabetes mellitus (T2DM) has been recently recognized as a potent trigger of bullous pemphigoid.

Case summary: A 75-year old Filipino female presented with a 2-month history of pruritic tense bullae which started on the lower extremities and later on became generalized. She had absent mucosal lesions. She had a history of hypertension, cerebrovascular disease and a recent diagnosis of type 2 diabetes mellitus. She was started on Linagliptin 4 months prior to the onset of the tense blisters. Clinical findings were confirmed by histopathologic and direct immunofluorescence studies.

Conclusion: The population mostly affected by BP is the elderly, who oftentimes exhibit co-morbid diseases. Awareness of factors, like medications and diseases significantly associated with BP is therefore warranted in the effective and long-term management of this blistering disease.





bullous pemphigoid, linagliptin, gliptin



More Articles


/* ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Conditionally display Abstract button ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ */ /* ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Conditionally display References button ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ */